Literature DB >> 6540194

The use of human cancer cell lines as a primary screening system for antineoplastic compounds.

G J Finlay, B C Baguley.   

Abstract

Exponentially growing cells of human cancer lines have been utilized to investigate the cytotoxic activity of antineoplastic agents. Different cancer cell lines differ greatly in their responsiveness to both clinical and experimental cytotoxic drugs. For example, sensitivities to 5-fluorouracil and cytosine arabinoside ranged over 15- and 30-fold respectively. Cell lines derived from carcinomas were more sensitive to 5-fluorouracil and less sensitive to cytosine arabinoside than was a leukaemic cell line. In general, colon carcinoma lines were most resistant to DNA-intercalating drugs, and a breast carcinoma and leukaemia line most sensitive. In a congeneric series of amsacrine analogues, in vitro patterns of activity against different lines were shown to correlate with activity against the Lewis lung mouse carcinoma in vivo. Results suggest that established cell lines manifest responsiveness to anticancer drugs consistent with that expected from their tumours of origin. This assay is economical, reproducible and convenient, and could be used to complement the human tumour stem cell assay in drug development studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540194     DOI: 10.1016/0277-5379(84)90169-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  10 in total

1.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Rapid chemosensitivity testing of human lung tumor cells using the MTT assay.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Application of a new preclinical drug screening system for cancer of the large bowel.

Authors:  W Scheithauer; M P Moyer; G M Clark; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines.

Authors:  J R Jett; N Saijo; W S Hong; Y Sasaki; H Takahashi; H Nakano; K Nakagawa; M Sakurai; K Suemasu; M Tesada
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  The PIT method: an automated in vitro technique for drug toxicity testing.

Authors:  R van Lambalgen; P Lelieveld
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

6.  In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture.

Authors:  R A Vescio; C H Redfern; T J Nelson; S Ugoretz; P H Stern; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells.

Authors:  G J Badiner; R D Hamilton; L H Li; B K Bhuyan
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

8.  In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay.

Authors:  Y Sasaki; F Kanzawa; H Takahashi; Y Matsushima; H Nakano; K Nakagawa; W S Hong; K Minato; Y Fujiwara; N Saijo
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

9.  Piper and Vismia species from Colombian Amazonia differentially affect cell proliferation of hepatocarcinoma cells.

Authors:  Leandro J Lizcano; Maite Siles; Jenifer Trepiana; M Luisa Hernández; Rosaura Navarro; M Begoña Ruiz-Larrea; José Ignacio Ruiz-Sanz
Journal:  Nutrients       Date:  2014-12-30       Impact factor: 5.717

10.  A Perspective on Expanding Our Understanding of Cancer Treatments by Integrating Approaches from the Biological and Physical Sciences.

Authors:  Emma J Fong; Carly Strelez; Shannon M Mumenthaler
Journal:  SLAS Discov       Date:  2020-04-16       Impact factor: 3.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.